Neurogene Inc (NGNE NASDAQ) stock market data APIs
$19.0789
1.14(6%)
as of September 12, 2025
Try our APIs with
free plan!
Neurogene Inc Financial Data Overview
Price chart is built with
Anychart
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Prev. Close
19.0789
Open
20.2209
High
20.5014
Low
18.7705
52 wk Range
6.875-74.49
Market Cap
271 M
Shares Outstanding
14 272 K
EPS
-1.05
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neurogene Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurogene Inc data using free add-ons & libraries
Get Neurogene Inc Fundamental Data
Neurogene Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -92 558 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: -1.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurogene Inc News
New
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
The biotech Rocket Pharmaceuticals said the Food and Drug Administration would allow it to continue a gene therapy trial the agency had put on hold in late May, when a patient in the trial died. In th...
Short Report: Bears bite into Krispy Kreme after another weak earnings report
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the ...
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
The best biotech stocks to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. Regulatory hurdles make finding biotech stocks ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
